Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Journal Information
Full Title: Leukemia
Abbreviation: Leukemia
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Competing interests The authors declare no competing interests."
Funding Disclosure
Evidence found in paper:
"Funding This study was supported by the Swiss Group for Clinical Cancer Research (SAKK), the LOA IV funds, managed by curafutura, santésuisse and pharmaSuisse, and a grant from Krebsliga Schweiz and Swiss State Secretariat of Education, Research and Innovation (SERI). TZ, TP, SS, SA, UN, GR, JG, ZM, SH, AR, CR, CD: nothing to disclose. UM reports honoraria and travel support Celgene/BMS. EL reports consultancy for Celgene/BMS."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025